Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
811
resultados
Última actualización
09/04/2026 [07:06:00]
Resultados 109 a 218 de 811
Resumen de: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Resumen de: EP4721659A2
0001 Devices are provided for measurement of an analyte concentration, e.g., glucose in a host. The device can include a continuous analyte sensor 34 configured to generate a signal associated with a concentration of an analyte, a reference electrode 30, and a sensing membrane 32 located over the working electrode 38. The sensing membrane comprises a diffusion resistance domain configured to control a flux of the analyte therethrough. The diffusion resistance domain comprises one or more zwitterionic compounds and a base polymer comprising both hydrophilic and hydrophobic regions.
Resumen de: WO2026065646A1
Disclosed are a biocompatible film for a biosensor and a glucose sensor. The biocompatible film is prepared by coating a film solution by means of a coating process. The film solution comprises a cofactor-grafted polymer, an organic solvent, and a buffer solution. An end portion of each branch of the cofactor-grafted polymer has a cofactor grafted thereto. The backbone of the cofactor-grafted polymer is one or more of polyurethane, polyvinyl alcohol, a polyvinyl alcohol derivative, polyvinylpyrrolidone, a polyvinylpyrrolidone derivative, polyvinylpyridine, and a polyvinylpyridine derivative. The branches of the cofactor-grafted polymer are one or more of acetic acid, butyric acid, ethyl butyrate, caproic acid, and ethyl hexanoate. The biocompatible film can achieve precise regulation of chemical substance permeability, expand the linear detection range of the biosensor for chemical substances, and provide the cofactors required during chemical substance detection, thereby improving the stability and durability of the biosensor.
Resumen de: AU2026201926A1
22514182_1 (GHMatters) P118105.AU.1 Embodiments relate to an adaptive glycemia monitoring and forecasting system that includes an event monitor configured to receive blood glucose levels of an individual or information about an activity performed by the individual, and generate an event output. The system includes a control module configured to pull observation data, predictor variables, and population estimated vector of covariate weightings coefficients from a database, and generate updated estimated vector of covariate weightings coefficients for the individual user based on the event output. The updated estimated vector of covariate weightings coefficients are determined by a cross-entropy loss objective function. The updated estimated vector of covariate weightings coefficients are used to predict at least one or more of a predicted hypoglycemia state, a predicted normal glycemia state, or a predicted hyperglycemia state for the individual user. the individual user. ar a r
Resumen de: WO2026067891A1
A compensation method and device for a continuous glucose monitor includes: acquiring a real-time glucose value of a user continuously(S101); determining a user type and a glucose trend type according to the real-time glucose value, where the user type includes at least a first user type and a second user type(S102); determining, based on the real-time glucose value, whether a compensation start condition is satisfied; starting a compensation algorithm if the compensation start condition is satisfied(S103); determining a compensation formula based on the real-time glucose value, the glucose trend type, and the user type(S104); and obtaining, based on the real-time glucose value and the compensation formula, a compensated glucose value until a compensation stop condition is satisfied(S105).
Resumen de: US20260095261A1
Method, system and computer program product for providing real time detection of analyte sensor sensitivity decline is continuous glucose monitoring systems are provided.
Resumen de: AU2026201994A1
22510489_1 (GHMatters) P117930.AU.1 Provided are a system and method for an artificial pancreas having multi-stage model predictive control to minimize and/or prevent occurrence of hypoglycemia associated with Type 1 diabetes. The control implements predictive modeling of a probability of glucose uptake associated with exercise based on at least one exercise 5 profile for a subject with Type 1 diabetes. Based on the probability, the control implements an automatic adjustment of basal insulin infusion to counteract a risk of exercise-induced hypoglycemia in advance of the subject engaging in the exercise. The control further implements adjustment of such infusion based on real-time signaling of exercise likely to induce hypoglycemia. Prior to consumption of a meal, the control 10 further implements adjustment of a meal-time bolus so as to account for the effect of delay in glucose uptake resulting from exercise previously engaged in by the subject. Consequently, the control acts to minimize and/or prevent hypoglycemia from occurring both during and immediately after the subject engages in exercise. ar a r
Resumen de: AU2026201970A1
MARKED-UP COPY MARKED-UP COPY Disclosed are systems and methods for generating graphical displays of analyte data and/or health information. In some implementations, the graphical displays are generating based on a self-referential dataset that are modifiable based on identified portions of the data. The modified graphical displays can indicate features in the analyte data of a host. ar a r
Resumen de: AU2026202005A1
Methods, devices, and kits are provided for determining a recommended insulin dose to be administered to user based upon analyte data determined by an analyte sensor. ar a r
Resumen de: WO2026071284A1
A ring-structured non-invasive blood glucose sensor according to the present invention comprises: a transmission unit which is provided in a first ring structure, and which generates electromagnetic waves and irradiates same toward the center of the first ring structure; an active element which is provided in a second ring structure that is smaller than the first ring structure and is disposed inside the first ring structure, and which amplifies the electromagnetic waves irradiated by the transmission unit so that the amplified electromagnetic waves are directed toward an object to be inspected disposed inside the second ring structure; a reception unit which is provided to be spaced apart from the transmission unit in the first ring structure, and which receives electromagnetic waves reflected or scattered from the object to be inspected; and a conductor, which is disposed to be adjacent to the first ring structure and the second ring structure, propagates the electromagnetic waves amplified by the active element toward the object to be inspected, by virtue of a space defined by a conductor, and strengthens a resonance phenomenon by strengthening an electromagnetic field within the defined space.
Resumen de: US20260091175A1
The invention discloses a drug delivery system with graphical user interface comprises a detection device, for detecting the blood glucose level of the user; an infusion device, for infusing a drug into the user's body; and a control device, wirelessly communicated with the detection device and the infusion device, the control device controlling the drug delivery of the infusion device, and the control device provided with a graphical user interface, the graphical user interface comprising a main screen, the main screen comprising an insulin information display area and a blood glucose information display area, wherein the insulin information display area comprising insulin infusion status information, the graphical user interface displays the insulin infusion status information in a graphical and/or textual manner, to facilitate the user to intuitively know the insulin infusion status information and blood glucose information at that time.
Resumen de: AU2026201971A1
Systems and methods are provided to provide guidance to a user regarding management of a physiologic condition such as diabetes. The determination may be based upon a patient glucose concentration level. The glucose concentration level may be provided to a stored model to determine a state. The guidance may be determined based at least in part on the determined state. ar a r
Resumen de: AU2024280120A1
Blood glucose level measurement includes a light source configured to irradiate light to a subject; a monochrome part configured to separate wavelength components of the light that is reflected and scattered from the subject; a light receiver configured to receive the light transmitted via the monochrome part and to generate electrical signals based on the received light; and a processor configured to extract information on the blood glucose level of the subject based on a frequency shift of the light due to the Raman effect.
Resumen de: EP4717171A2
According to the present disclosure, an applicator for a continuous blood glucose measurement device, the applicator being operated by attaching a body attachment unit to the body of a user, the body attachment unit including a sensor member which is inserted into the body of the user in order to measure the blood glucose, comprises: a main case; a plunger to which the body attachment unit is detachably coupled and which is installed in the main case to be movable from a first position to a second position so that the body attachment unit can be discharged to the outer direction of the main case; a needle which is detachably coupled to the body attachment unit so as to be inserted into the body of the user along with the sensor member; and a needle separating unit which separates the needle from the body of the user by moving the needle in the direction opposite to the discharge direction of the plunger, wherein the needle separating unit includes a locking unit which can be assembled with the plunger in the manner of being engaged with one side of the plunger.
Resumen de: US12588838B1
Introduced here are diabetes management platforms able to examine glucose measurements associated with a subject to discover patterns indicative of similar behaviors/circumstances. More specifically, a diabetes management platform can acquire multiple data series generated by a glucose monitoring device that monitors the blood glucose level of an individual over multiple time intervals. The diabetes management platform can then apply a similarity algorithm to produce a distance measure (also referred to as a “similarity measure”) for each data series. For example, the diabetes management platform may, for each data series, perform dynamic time warping to produce a distance measure with respect to each of the other data series. The diabetes management platform can identify patterns indicative of similar behaviors/circumstances based on these distance measures.
Resumen de: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Resumen de: WO2026064554A1
Provided herein are methods of treating various eye disorders, including, for example, wet age-related macular degeneration (wAMD) or diabetic retinopathy (DR), using an anti-VEGF therapy, such as an anti-VEGF antibody conjugate.
Resumen de: US20260089162A1
Systems, devices, and methods are disclosed for wireless communication of analyte data. In embodiments, a method of using a diabetes management partner interface to configure an analyte sensor system for wireless communication with a plurality of partner devices is provided. The method includes the analyte sensor system receiving authorization to provide one of the partner devices with access to a set of configuration parameters via the diabetes management partner interface. The set of configuration parameters is stored in a memory of the analyte sensor system. The method also includes, responsive to input received from the one partner device via the diabetes management partner interface, the analyte sensor system setting or causing a modification to the set of configuration parameters, according to a system requirement of the one partner device.
Resumen de: US20260083909A1
A reinforcement learning process with self attention is used for insulin dosing decisions in an automated medical system. The State-Action-Reward-Next State (SARS) sequence is used. The state represents the current condition, including recent continuous glucose monitoring readings, insulin doses, meal information, and potentially other relevant factors like time of day or physical activity levels. Based on this state, the agent takes an action by deciding on an insulin dose. It then receives a reward, a numerical value quantifying the quality of the action, based on resulting glucose levels and their proximity to the target range. This leads to a new state, and the process repeats. Through this iterative process, the algorithm updates the neural network weights, allowing the agent to learn which actions lead to better outcomes in different states.
Resumen de: WO2026062700A1
The present disclosure relates to a system and method to predict the post- prandial glucose response in the individuals type 2 diabetes mellitus (T2DM) in India by taking sample of patients with T2DM from various locations across India and fitting them with continuous glucose monitors (CGM) and calculating the postprandial glucose response based on the different meal intakes by the patients. The present disclosure further relates to the utilization of k-means clustering models to classify food types based on nutritional information and classification of patients. The present disclosure also relates to utilizing XGBoost to predict postprandial blood glucose responses based on patient phenotypes and food categories and providing personalized recommendations taking into account meal type, preferences, and regional influences which would allow patients with T2DM to eat and drink foods to maintain their blood sugar within prescribed limits and prevent disease progression.
Resumen de: US20260083363A1
This document describes medical systems for detecting biological analytes. For example, this document describes sensors for the continuous monitoring of biological analytes, such as glucose and/or lactate, in aqueous solutions and body fluids (e.g., blood) based on a readout of fluorescence or luminescence signals.WO
Resumen de: US20260083357A1
Systems and methods for determining a glucose value for a user are disclosed herein. The method includes receiving a plurality of data inputs associated with biometric data of the user, the plurality of data inputs including at least one data input representative of a past estimated glucose value of the user and processing the plurality of data inputs with a multi-headed temporal convolutional neural network to generate a blood glucose value for the user. The method also includes providing a notification to the user based at least in part on the blood glucose value.
Resumen de: US20260088150A1
Techniques disclosed herein relate to operating a fluid delivery device in a personalized manner based at least in part on historical data of a patient. In some embodiments, the techniques involve obtaining historical meal data for the patient associated with historical meal events for the patient; determining a meal content based at least in part on the historical meal data; obtaining nutritional information associated with the meal content and historical meal events for the patient; determining, by a control system, a dosage of insulin based at least in part on the nutritional information and the historical meal events; and operating, by the control system, an actuation arrangement of the infusion device to deliver the dosage of the insulin to the patient.
Resumen de: US20260083912A1
Exemplary embodiments account for differing needs of a user over the menstrual cycle of the user to better control the blood glucose concentration of the user. The exemplary embodiments may be realized in control systems for medicament delivery devices that deliver medicaments, such as medicaments that regulate blood glucose concentration levels. Examples of such medicaments that regulate blood glucose concentration levels include insulin, glucagon, and glucagon peptide-1 (GLP-1) agonists. The exemplary embodiments are able to better tailor the dosages of the medicament delivered to the user with the medicament delivery device to reduce the risk of hyperglycemia and hypoglycemia and help reduce blood glucose concentration excursions.
Resumen de: US20260083358A1
In implementations of systems for determining a similarity of sequences of glucose values, a computing device implements a similarity system to receive input data describing a sequence of user glucose values measured by a continuous glucose monitoring (CGM) system. The similarity system computes similarity scores for a plurality of sequences of glucose values by comparing each glucose values included in the sequence of user glucose values with ever glucose value included in each sequence of the plurality of sequences. A particular sequence of glucose values that is associated with a highest similarity score is identified. The similarity system determines an externality associated with the particular sequence. The similarity system generates an indication of the externality for display in a user interface.
Resumen de: WO2025046158A1
The invention relates to a method for controlling glucose in a flexible-structure bihormonal artificial pancreas that manages optional meal and/or exercise alerts by means of coordinated control actions, comprising: measuring a plasma glucose signal; calculating an incremental plasma glucose measurement (y); defining a model for incremental plasma glucose; defining a carbohydrate ingestion as dependent on a carbohydrate content estimated by the patient; defining an expected postprandial incremental plasma glucose y*(s) according to an insulin bolus that has been administered; defining a corrected incremental plasma glucose y̅(s), a corrected insulin infusion ū(s) and a corrected carbohydrate ingestion d̅(s); defining a virtual control action μ(s), divided between regulatory actions μ r and counterregulatory actions μ cr ; and calculating the control actions using a 2-DOF feedback controller with a prefilter having a nominal value F r (s).
Resumen de: AU2024351716A1
A method of non-invasive determination of the blood glucose concentration in the patient's tissue based on a radio noise signal received using an antenna brought close to the patient's skin according to the invention involves use of the radio noise signal is measured using a passive radiometer and additionally the method includes the following steps: a step of obtaining transformation coefficients, a step of measuring the temperature of the tissue surface, a step of measuring the temperatures of the active elements of the receiving chain of the radiometer, a step of measuring the currents consumed by the active elements of the receiving chain of the radiometer, a step of measuring the power of the radio noise signal originating from the tissue, and a step of determining the blood glucose concentration based on the aforementioned values. The invention also relates to a computer program, a radiometer, and a device for determining glucose concentration.
Resumen de: US20260083911A1
Enclosed herein are methods and systems for establishing communication protocols between wireless devices in infusion pump systems. Infusion pump systems can include a number of components capable of wireless communication with one or more other components including an infusion pump, a continuous glucose monitoring (CGM) system, and a smartphone or other multi-purpose consumer electronic device (i.e., remote control device). Communications among these devices can be coordinated to ensure reliable and consistent transmission of medical data.
Resumen de: US20260088171A1
An ambulatory glucose profile (AGP) intelligent interpretation and insulin adjustment method based on an expert system includes: establishing a knowledge base in an inference mechanism; constructing an interpretation and decision support expert system with a simplified expert system architecture based on the knowledge base; constructing a patient problem analysis tree in three dimensions of hypoglycemia, blood glucose fluctuation, and hyperglycemia of patients; expanding each rule with expert AGP interpretation and empirical data; constructing a basal insulin dosage adjustment rule and a mealtime insulin dosage adjustment rule based on an interval type-2 fuzzy expert system; and adjusting a node of the patient problem analysis tree based on the interpretation and decision support expert system and a group of the patient, and providing a decision suggestion in combination with the basal insulin dosage adjustment rule and the mealtime insulin dosage adjustment rule.
Resumen de: EP4715836A1
A meal monitoring apparatus according to an embodiment of the present invention includes a data receiving unit configured to receive measurement data of parameters related to an ear of a target object and blood glucose data of the target object; a first estimated time calculating unit configured to calculate a first estimated time estimated as a food intake activity time of the target object based on the measurement data; a second estimated time calculating unit configured to calculate a second estimated time estimated as a glucose absorption time of the target object based on the blood glucose data; and a meal time calculating unit configured to calculate a meal time of the target object based on the first estimated time and the second estimated time.
Resumen de: EP4715554A2
One or more embodiments of the present disclosure may include an insulin delivery system that includes an insulin delivery device, a user interface that includes multiple user-selectable icons or buttons each representing different meal characteristics, memory to store one or more user-specific dosage parameter, and a processor in communication with the memory and adapted to receive blood glucose data. The processor may also be adapted to determine initial meal characteristics associated with each of the user-selectable icons or buttons based on at least one of the user-specific dosage parameters. The processor may also be adapted to update the meal characteristics associated with each of the user-selectable icons or buttons based upon the blood glucose data.
Resumen de: EP4671882A2
The present disclosure relates to a system for closed loop control of glycemia. In one arrangement, the system comprises: an insulin delivery device; a user interface for inputting patient data, the patient data including a basal insulin profile, an insulin-to-carbohydrate ratio, and meal data; and a controller in communication with the user interface and the insulin delivery device and configured to receive glucose data. The controller is further configured to execute: estimating an amount of active insulin in the patient, the active insulin not including the basal insulin profile, determining a meal carbohydrate value from the meal data, estimating a physiological glucose for the patient and a rate of change of physiological glucose based in part on the glucose data, determining an attenuation factor based on the physiological glucose and the rate of change of the physiological glucose, determining a meal bolus based on meal data, the insulin-to-carbohydrate ratio, and the determined attenuation factor, modifying the determined meal bolus based on the estimated amount of active insulin in the patient, and transmitting a request to deliver the modified meal bolus to the insulin delivery device.
Resumen de: WO2026060397A2
An analyte sensor system may include an analyte sensor configured to generate a raw sensor signal associated with an analyte concentration of a host. Sensor electronics may be configured to generate estimated analyte values from the raw sensor signal, determine a rate of change for the estimated analyte values or the raw signal, determine a working electrode temperature, and determine an elapsed time since sensor insertion. The sensor electronics may improve sensor performance by determining a prediction horizon as a function of at least one of the elapsed time and the working electrode temperature, determining a time-lag- compensated estimated analyte value for one of the estimated analyte values as a function of the determined prediction horizon and the rate-of-change, and adjusting estimated analyte values by applying a correction that is a function of the estimated analyte values.
Resumen de: WO2026059033A1
Disclosed, according to various embodiments of the present invention, is a method for adjusting an insulin injection amount based on predicted blood glucose. The method may comprise the steps of: predicting a future blood glucose value on the basis of the current blood glucose value and an insulin injection history; determining a future blood glucose state on the basis of the future blood glucose value and a predefined correction factor; and adjusting an insulin injection amount so as to correspond to the future blood glucose state.
Resumen de: AU2026201602A1
Systems and methods disclosed provide ways for Health Care Professionals (HCPs) to be involved in initial patient system set up so that the data received is truly transformative, such that the patient not just understands what all the various numbers mean but also how the data can be used. For example, in one implementation, a CGM device is configured for use by a HCP, and includes a housing and a circuit configured to receive a signal from a transmitter coupled to an indwelling glucose sensor. A calibration module converts the received signal into clinical units. A user interface is provided that is configured to display a measured glucose concentration in the clinical units. The user interface is further configured to receive input data about a patient level, where the input data about the patient level causes the device to operate in a mode appropriate to the patient level. ar a r
Resumen de: US20260076628A1
A system is provided comprising external device(s), tracking device(s) configured to generate blood glucose level data for tracked individual(s), and an alert device for management of alerts generated at the external device(s). The alert device comprises processor(s) and memory device(s). The memory device(s) comprise computer readable code that, when executed by the processor(s), causes the processor(s) to receive input data comprising blood glucose level data received from the tracking device(s), to determine an alert setting for an alert to be generated at an external device of the external device(s) based on the input data, and to generate a signal that causes the alert to be generated at the external device. The alert setting includes an identification of the external device where the alert is to be generated, an alert magnitude, and/or the alert type, with the alert type including an audible alert, a haptic alert, and/or a visual alert.
Resumen de: US20260077116A1
An infusion system is disclosed comprising: a device for delivering insulin to a user, the device including a reservoir and a micropump for pumping the insulin from the reservoir into tissue of a user; and a cartridge for securing a cartridge insert that includes (a) an infusion needle configured to infuse the insulin and introduce a CGM sensor into the user or (b) an introducer needle for introducing an infusion catheter and the CGM sensor into the user, the cartridge configured to move from (1) a first position, wherein the infusion needle or an introducer needle is above the tissue of the user to (2) an second position, wherein the infusion needle or the introducer needle is in a deployed position inserted into tissue of the user, wherein the cartridge includes a locking mechanism to lock the cartridge insert into the cartridge.
Resumen de: US20260076591A1
Systems, devices and methods are provided for incorporating a medication delivery device into an integrated management system. The integrated management system may be an integrated diabetes management system and may include a glucose monitor, a connected insulin pen, and software. The integrated management system may produce a plurality of reports that may include data related to analyte levels (e.g., glucose levels) and medication delivered (e.g., insulin delivered). The integrated system may also include a mode in which certain types of data are no longer shared and/or stored if the user is not signed into an account. The types of data shared and/or stored when the user is not signed into an account may differ from the types of data shared and/or stored when the user is signed into an account.
Resumen de: EP4712093A2
A method may include obtaining blood glucose level readings over a diurnal period for each of a plurality of days and determining an estimated variability of the blood glucose levels over the diurnal period for the plurality of days. The method may also include modifying, based on the estimated variability of the blood glucose level, a target blood glucose level to a modified target blood glucose level, and delivering insulin, using an insulin pump, during the diurnal period based on the modified target blood glucose level.
Resumen de: EP4712100A2
0001 An Adaptive Advisory Control (AA Control) interactive process involving algorithm-based assessment and communication of physiologic and behavioral parameters and patterns assists patients with diabetes with the optimization of their glycemic control. The method and system may uses all available sources of information about the patient; (i) EO Data (e.g. self-monitoring of blood glucose (SMBG) and CMG), (ii) Insulin Data (e.g. insulin pump log files or patient treatment records), and (iii) Patient Self Reporting Data (e.g. self treatment behaviors, meals, and exercise) to: retroactively assess the risk of hypoglycemia, retroactively assess risk-based reduction of insulin delivery, and then report to the patient how a risk-based insulin reduction system would have acted consistently to prevent hypoglycemia.
Resumen de: EP4710855A2
A method for optional external calibration of a calibration-free glucose sensor uses values of measured working electrode current (Isig) and EIS data to calculate a final sensor glucose (SG) value. Counter electrode voltage (Ventr) may also be used as an input. Raw Isig and Vcntr values may be preprocessed, and low-pass filtering, averaging, and/or feature generation may be applied. SG values may be generated using one or more models for predicting SG calculations. Complex redundancy may be employed to take operational advantage of disparate characteristics of two or more dissimilar, or non-identical, sensors, including, e.g., characteristics relating to hydration, stabilization, and durability of such sensors. Fusion algorithms, EIS, and advanced Application Specific Integrated Circuits (ASICs) may be used to implement use of such redundant glucose sensors, devices, and sensor systems in such a way as to bridge the gaps between fast start-up, sensor longevity, and accuracy of calibration-free algorithms.
Resumen de: US12576209B1
A housing for hypodermic device including a housing assembly, a hypodermic device housed therein, twist off top and bottom caps. The housing assembly includes an upper and lower ends, exterior and interior walls. The exterior and interior walls definine a vacuum sealed in-between space, and the interior wall defines an interior cavity. The top and bottom caps include first and second tabs, respectively. The hypodermic device has proximal and distal ends. The hypodermic device includes auto injectors such as epinephrine auto injector, insulin auto injector or similar. The exterior and interior walls are vacuum sealed layers made of a rigid material that protect the hypodermic device from impact and accidental activation and keep the hypodermic device at a range of temperature for a longer period of time. A ring attachment is adjacent to the upper end, and it secures to backpacks, purses, garments or similar.
Resumen de: US20260069781A1
The exemplary embodiments attempt to identify impending hypoglycemia and/or hyperglycemia and take measures to prevent the hypoglycemia or hyperglycemia. Exemplary embodiments may provide a drug delivery system for delivering insulin and glucagon as needed by a user of the drug delivery system. The drug delivery system may deploy a control system that controls the automated delivery of insulin and glucagon to a patient by the drug delivery system. The control system seeks among other goals to avoid the user experiencing hypoglycemia or hyperglycemia. The control system may employ a clinical decision support algorithm as is described below to control delivery of insulin and glucagon to reduce the risk of hypoglycemia or hyperglycemia and to provide alerts to the user when needed. The control system assesses whether the drug delivery system can respond enough to avoid hypoglycemia or hyperglycemia and generates alerts when manual action is needed to avoid hypoglycemia or hyperglycemia.
Resumen de: US20260069779A1
Provided is a wearable medical device that includes a processor or logic circuitry. The wearable medical device may include a memory storing instructions that, when executed by the processor or logic circuitry, configure the wearable medical device to determine, by the processor or the logic circuitry, that an event affecting a blood glucose measurement value trend of a user has occurred. Based on the occurrence of the event, the processor or the logic circuitry may select a mode of operation of the analyte sensor, and generate a signal indicating the selected mode of operation. The mode of operation may correspond to a sampling frequency of a physical attribute or physiological condition of a user of the wearable medical device.
Resumen de: US20260069218A1
Disclosed is a management device for displaying glucose information. The screen of the management device is divided into the plurality of display areas, at least comprising a first display area for displaying the status of the management device, a second display area for displaying real-time glucose information, and a third display area for displaying historical glucose concentration information. The user can intuitively and easily get the glucose information in the body.
Resumen de: US20260069765A1
An infusion system is disclosed comprising: a device for delivering insulin into tissue of a user; and a cartridge assembly including an integrated infusion catheter and CGM sensor subassembly and an introducer needle for introducing the integrated infusion catheter and CGM sensor subassembly into the tissue of the user, wherein the cartridge assembly configured to move from (a) first position, wherein the integrated infusion catheter and CGM sensor subassembly is in a first position above the tissue of the user to (b) a second position, wherein the integrated infusion catheter and CGM sensor subassembly is in a deployed position inserted into tissue of the user.
Resumen de: US20260069780A1
Techniques disclosed herein related to controlling insulin delivery. In some embodiments, the techniques may involve delivering insulin via an insulin infusion device according to a closed-loop mode of delivery. The techniques may further involve determining, at a first time point, insulin delivery is to be switched from the closed-loop mode of delivery to a second mode of delivery. The techniques may further involve switching operation of the insulin infusion device to the second mode of delivery such that insulin is delivered via the insulin infusion device according to the second mode of delivery.
Resumen de: US20260069173A1
Various examples are directed to a glucose sensor comprising a working electrode to support an oxidation reaction and a reference electrode to support a redox reaction. The reference electrode may comprise silver and silver chloride. The Glucose sensor may also comprise an anti-mineralization agent positioned at the reference electrode to reduce formation of calcium carbonate at the reference electrode.
Resumen de: WO2026054488A1
The present invention relates to a method for managing a diabetic patient using a continuous glucose monitor, the method being characterized by comprising: a data reception step of receiving measurement data from a continuous glucose monitor; a data calculation step of calculating a sensor wearing time, a time within a specific glucose range, a time less than a first glucose value, a time greater than a second glucose value, EhyperE (whether a glucose level continuously exceeds 250 mg/dL for 2 hours or more), a time during which a glucose level is less than 54 mg/dL, and food intake time detection (FITD) by using the measurement data; and a data classification step of including a matrix part for classifying into one or more cases according to a time ratio, over a period of one week, of the sensor wearing time, the time within a specific glucose range, the time less than a first glucose value, the time greater than a second glucose value, EhyperE (whether a glucose level continuously exceeds 250 mg/dL for 2 hours or more), the time during which a glucose level is less than 54 mg/dL, and the food intake time detection, and an insulin and lifestyle correction part for classifying into one or more cases according to the number of times a predetermined glucose level occurs in a predetermined time period.
Resumen de: US20260069776A1
Provided are a method, apparatus, and computer program for providing a notification according to a period of use of a drug infusion device. A time point at which the drug infusion device switches from an inactive mode to an active mode may be determined as a use start time point. Also, an impending expiration notification indicating that expiration of a period of use of the drug infusion device is imminent may be provided at a first time point after a certain period from the use start time point, based on a usable period and a user set time of the drug infusion device. In addition, an expiration notification indicating that the period of use of the drug infusion device has expired may be provided at a second time point after the usable period from the use start time point.
Resumen de: WO2026055546A2
Methods, systems and devices for providing health information to an individual. Methods may include predicting a subject's glucose sensitivity risk based on recorded sleep brain activity signals, and optionally providing an output to the subject based on the predicted glucose sensitivity risk. Methods may include providing personalized proactive behavioral guidance for a subject for an awake period following a sleep period, the proactive behavior guidance based on at least one of predicted glucose sensitivity risk or quality of sleep.
Resumen de: US20260069778A1
The invention discloses an automatic detection method based on the change rate of the difference between the actual blood glucose values, including: obtaining an actual blood glucose value of the user at the current time; obtaining a historical actual blood glucose value of the user at the previous time, and calculate a difference between the actual blood glucose values at the current time and at the previous time; calculating a change rate of the difference between the actual blood glucose values at the current time; and comparing the change rate of the difference between the actual blood glucose values at the current time with a preset threshold, and determining an event type based on the comparing result. Based on the determined event type, the artificial pancreas can automatically adjust the corresponding infusion strategy to achieve closed-loop control of the artificial pancreas.
Resumen de: WO2024229007A2
Embodiments relate to systems and methods for developing and implementing a model. Developing the model can involve receiving an insulin dosing rule (IDR) including plural metabolic states (Xs) and corresponding insulin dosage recommendations (Us), generating a saturated data set with the plural Xs and corresponding Us so that the saturated data set has optimal data density, generating a saturated look-up table (STL) with the saturated data set, and encoding the STL into a neural network. Implementing the model can involve receiving a measurement indicative of a metabolic state (Xm), implementing a model a SLT encoded into a neural network, the SLT including a saturated data set of optimal data density, wherein implementation of the model applies the Xm to the SLT to identify a corresponding U, and monitoring, analyzing, or influencing a concentration of glucose levels in a fluid using the identified U.
Resumen de: EP4708311A2
0001 An insulin delivery monitoring system that includes an insulin delivery device and a controller configured to perform or control performance of operations. A method of insulin delivery include obtaining one or more blood glucose readings of a user, and, based on the blood glucose readings, generating a set of insulin delivery actions that may include delivery of a baseline basal rate or predefined variations of the baseline basal rate.
Resumen de: EP4708310A2
0001 A method of insulin delivery, the method may include obtaining one or more blood glucose readings from a flash glucose monitor, where the blood glucose readings may be obtained in response to a user invocation of the flash glucose monitor. The method may also include generating multiple insulin delivery profiles of insulin delivery actions over multiple diurnal time segments based on the one or more blood glucose readings. The method may additionally include selecting one of the delivery profiles that is projected to approximate a target blood glucose level, and delivering insulin according to the selected delivery profile.
Resumen de: EP4706531A2
The present invention relates to a sensor applicator assembly for a continuous glucose monitoring system and provides a sensor applicator assembly for a continuous glucose monitoring system, which is manufactured with a sensor module assembled inside an applicator, thereby minimizing additional work by a user for attaching the sensor module to the body and allowing the sensor module to be attached to the body simply by operating the applicator, and thus can be used more conveniently. A battery is built in the sensor module and a separate transmitter is connected to the sensor module so as to receive power supply from the sensor module and be continuously used semi-permanently, thereby making the assembly economical. The sensor module and the applicator are used as disposables, thereby allowing accurate and safe use and convenient maintenance.
Resumen de: EP4706532A2
The present disclosure relates to a continuous blood glucose measurement body attachment unit, and provides a continuous blood glucose measurement body attachment unit, which is manufactured in an assembled state in an applicator so as to minimize separate additional operations, such that the body attachment unit can be attached to the body with only a simple operation of the applicator and, particularly, the body attachment unit has a wireless communication chip so as to be capable of communicating with an external terminal, thereby enabling simple and convenient usage without an additional operation in which a separate transmitter must be connected and enabling maintenance to be more easily performed, and after the body attachment unit is attached to the body, an operation starts by the control of a user, such that an operation start time point can be adjusted to an appropriate time point according to the needs of the user, and an operation can start in a stabilized state, such that blood glucose can be more accurately measured.
Resumen de: EP4706533A2
The present disclosure relates to a continuous glucose monitoring device, in which a body attachment unit is manufactured so as to be assembled in an applicator, thereby minimizing additional work for a user in attaching the body attachment unit to a body, and allowing attachment of the body attachment unit to the body simply by operation of the applicator. In particular, a wireless communication chip is provided in the body attachment unit to enable communication with an external terminal, thereby enabling simple and convenient use without additional work of connecting a separate transmitter, and allowing easier maintenance. In addition, the continuous glucose monitoring device is activated by a user's operation after the body attachment unit is attached to the body, such that an activation start time can be adjusted to a time appropriate to the user's needs, and the continuous glucose monitoring device can be activated in a stabilized state, and thereby can monitor blood glucose more accurately.
Resumen de: US12573507B1
A programmatically generated AI avatar includes a customizable personality module, acting as the embodied interface for a powerful AI “mind” that delivers personalized coaching to improve user health, well-being, and longevity. The system uses machine learning, large language models, and biometric modeling to synthesize real-time, multi-modal health data—including sleep, nutrition, glucose, mood, and activity—and generate forward-prescribed KHAs. Unlike human coaches, it continuously adapts based on context and behavior, targeting the root cause: metabolic dysfunction—namely by restoring healthy, sustainable body composition through the preservation or building of lean muscle mass and reduction of excess fat. KHAs can also be shared with friends or programmatically generated AI avatars, allowing for coordinated action, emotional support, and accountability through social connection—further reinforcing positive behavior and adherence. The system's reinforcement learning engine incorporates both individual response data and anonymized population-level insights to optimize recommendations over time, learning which interventions are most effective for users with similar physiological and behavioral profiles. First validated with Olympic athletes—resulting in measurable improvements and medal-winning outcomes—this system offers a scalable, emotionally intelligent coaching enginethat exceeds human capability, designed for the ultimate purpose of supporting sustainab
Resumen de: EP4678094A2
The present disclosure relates to a continuous blood sugar measuring sensor member, wherein: since an electrode layer formed on one surface of a substrate is connected to a sensor contact point part on the other surface of the substrate through a via hole and thus two electrode layers may be formed on different opposite surfaces without having to be formed on the same surface of the substrate, the width of the substrate may be further reduced and an overall minimized and simplified structure may be ensured; since an electrode connection layer formed at the via hole is not formed in a shape of filling the via hole but is formed only on the inner circumferential surface, a filling defect occurring in a process of filling the via hole and a fault in electrical connection according thereto may be prevented and thus a more stable structure may be ensured; and since a plurality of via holes are formed, despite damage to or the occurrence of a defect in an electrode connection layer formed at one of the via holes, electrical connection is maintained by electrode connection layers formed at the remaining via holes, and thus more stable performance may be maintained.
Resumen de: US20260061122A1
A device in accordance with an embodiment of the present technology includes a port through which the device receives and dispenses infusion liquid (e.g., insulin solution) and a container that holds the infusion liquid. The device also includes a hub at a flowpath extending between the port and the container. The hub defines a first passage and a second passage in parallel with one another. The device further includes a conditioner and a check valve at the first and second passages, respectively. The conditioner conditions liquid moving between the container and the port by passing the liquid through an adsorbent filter and a mechanical filter. The check valve causes liquid moving between the port and the container to move preferentially via the first passage when flowing in one direction and to move preferentially via the second passage when flowing in an opposite direction.
Resumen de: WO2026047017A1
The present invention relates to glucose solutions for parenteral administration comprising glucose and a pharmaceutically acceptable form of iron, as well as to containers comprising, in separate chambers, said glucose solutions and a lipid emulsion for parenteral administration and/or an amino acid solution for parenteral administration.
Resumen de: AU2025279723A1
Described herein are fixed doses and dosing regimens for long-acting insulin receptor agonists suitable for once-weekly dosing, such as weekly basal insulin-Fc (BIF). ec e c
Resumen de: US20260061129A1
Exemplary embodiments may enable a user to schedule medicament bolus deliveries, such as insulin boluses, for future dates and times. The exemplary embodiments may provide the ability to delay a scheduled medicament bolus delivery by short periods of time. The user may reschedule a scheduled medicament bolus delivery by entering a new date and/or time for the medicament bolus delivery. Still further, a user may cancel a scheduled medicament bolus delivery. In addition, exemplary embodiments may enable multiple medicament bolus deliveries to be viewed and managed.
Resumen de: US20260066125A1
Provided are devices and systems for determining a blood glucose level for a subject, the device comprising a processor and a memory in communication with the processor, the device comprising: a receiving unit for obtaining a voice sample from the subject; an extraction unit for extracting at least one voice biomarker feature value from the voice sample for at least one predetermined voice biomarker feature; a determining unit for determining the blood glucose level for the subject based on the at least one voice biomarker feature value and a blood glucose level prediction model; and an output unit for outputting the blood glucose level or an output based on the blood glucose level for the subject.
Resumen de: WO2026045149A1
Provided in the present disclosure are an analyte concentration data-based processing device and a related method. The processing device comprises an acquisition module and a processing module. The acquisition module is configured to receive first analyte data related to a glucose concentration and second analyte data related to a ketone body concentration obtained by continuously monitoring at least two analytes of a target subject using an analyte sensor. The processing module is configured to acquire, on the basis of the first analyte data and the second analyte data, analyte concentration data comprising glucose concentration data and ketone body concentration data, acquire, on the basis of the analyte concentration data within a time period, at least one feature set, and determine, on the basis of the at least one feature set, target information at least comprising energy information. The energy information is the relationship between estimated energy intake and energy expenditure of the target subject, where the energy intake is the energy derived from ingested carbohydrates, and the energy expenditure is the energy that is consumed. Therefore, the convenience of evaluating the relationship between carbohydrate intake and consumption can be improved.
Resumen de: US20260066121A1
An embodiment may provide a blood glucose measurement method using a learning model, the method including obtaining a biosignal, generating biometric data from the biosignal, training a learning model with training biometric data, so as to output a blood glucose value, obtaining a blood glucose value corresponding to the biometric data from the biometric data via the learning model when training is completed, and providing, to a user, the blood glucose value corresponding to the biometric data.
Resumen de: US20260061128A1
Techniques disclosed herein relate to safe correction boluses. In some embodiments, the techniques involve obtaining a plurality of sensor glucose readings for a patient. The techniques may further involve determining, based on the plurality of sensor glucose readings that the patient has consumed a meal. The techniques may further involve in response to determining the patient has consumed the meal, reducing a hypoglycemia threshold from a first value to a second value lower than the first value. The techniques may further involve determining a correction bolus dosage based on the reduced hypoglycemia threshold.
Resumen de: WO2026047019A1
The present invention relates to amino acid solutions for parenteral administration comprising amino acids and a pharmaceutically acceptable form of copper, as well as to containers comprising, in separate chambers, said amino acid solutions and a lipid emulsion for parenteral administration and/or a glucose solution for parenteral administration.
Resumen de: WO2026045148A1
The present disclosure provides a method for producing views related to data on glucose and ketone bodies and a related system. The method comprises receiving analyte data from an analyte sensor; determining, on the basis of the received analyte data, analyte concentration data comprising glucose concentration data and ketone body concentration data; and displaying, on the basis of the analyte concentration data, on a display unit a plurality of views comprising a first view, wherein the first view comprises a graphical display generated on the basis of the analyte concentration data over a time period, the graphical display comprises a region representing the distribution of a plurality of data points, and the position of each data point is determined by the glucose concentration and the ketone body concentration at the same time. The present disclosure enables an observer to more conveniently analyze energy metabolism and is friendlier to the observer.
Resumen de: WO2026047021A1
The present invention relates to lipid emulsions for parenteral administration comprising an oil phase and a pharmaceutically acceptable form of selenium, as well as to containers comprising, in separate chambers, said emulsions and an amino acid solution for parenteral administration and/or a glucose solution for parenteral administration.
Resumen de: WO2026049829A1
A computer implemented method matching an individual's continuous metabolite monitoring traces with another individual's continuous metabolite monitoring traces begins by identifying a concentration level of a metabolite for a subject. Dividing metabolic states into ranges of concentration levels allows for transforming a concentration level into a symbol from a set of symbols, wherein the symbol represents a category of concentration levels. The method identifies one or more strings of symbols, wherein each string of symbols represents a series of one or more symbols corresponding to a series of transformed concentration levels represented by the symbols. A computer is programmed to determine a lexical distance between a first string from the one or more strings of symbols and a second string, wherein the lexical distance corresponds to a degree of similarity between the first string and the second string. The computer provides a search result for a search query based on the determined lexical distance.
Resumen de: WO2026049295A1
A blood glucose management system is disclosed, comprising a user terminal configured to capture an image of food, a processor, and an information providing device configured to provide the processor with blood glucose time-series information of a user prior to ingestion of the food. The processor is configured to execute a step of generating blood glucose trend prediction information of the user after ingestion of the food, based on data related to the food captured by the user terminal and the blood glucose time-series information. The user terminal is configured to display the blood glucose trend prediction information.
Resumen de: CN121038691A
Methods and systems for monitoring blood glucose levels of a subject are described, the method comprising the steps of: continuously acquiring electrocardiogram parameters of the subject, the electrocardiogram parameters comprising heart rate, heart rate variability, QT interval, and Tp/Rp ratio; inputting the acquired electrocardiogram parameters into a learning algorithm for processing the parameters; and outputting a continuously updated output value representative of the blood glucose level of the subject.
Resumen de: EP4702921A1
The present application relates to a method and apparatus for analyzing a blood glucose concentration, a device, a storage medium, and a computer program product. The method comprises: acquiring intensity sets corresponding to a plurality of photoplethysmography pulse wave sets for a target object in a target time period, the intensity set comprising an average alternating-current intensity and an average direct-current intensity; performing curve fitting on the plurality of intensity sets to obtain a fitting coefficient and a fitting bias; comparing the fitting bias with a bias range corresponding to the target object, and when it is determined that the fitting bias is not within the bias range, adjusting the fitting bias to obtain an adjusted fitting bias; and performing, on the basis of the adjusted fitting bias, curve fitting on the plurality of intensity sets to obtain an adjusted fitting coefficient, and taking the adjusted fitting coefficient as the blood glucose concentration of the target object in the target time period. By adopting the method, the accuracy of blood glucose concentration analysis can be improved.
Resumen de: WO2026043033A1
An electronic device is disclosed. The electronic device may identify that a user has started a meal. The electronic device may identify a blood sugar pattern after the meal is started, the blood sugar pattern being identified on the basis of continuous blood sugar data for the user obtained through a continuous blood sugar measurement sensor. The electronic device may identify foods consumed by the user during the meal on the basis of the blood sugar pattern. On the basis of the foods being identified, the electronic device may display, through a display, a user interface (UI) which includes the names of the foods and induces the user to record a meal event. On the basis of the foods not being identified, the electronic device may display, through the display, another UI for inducing the user to record the meal event without the names of the foods.
Resumen de: WO2026043816A1
In at least one embodiment, a hemoglobin measuring device may include a plurality of sensors, a display configured to present information, and a computing device in communication with the sensors and display and having a processor and a memory storing instructions executable by the processor. The instructions may include instructions to receive, from the sensors, measurements of one or more forms of glycated hemoglobin in a blood samples, determine a total fetal hemoglobin value in the blood sample by performing a peak area summation of all forms of fetal hemoglobin, subtract the total fetal hemoglobin value from 100 to derive a total adult hemoglobin value, determine a glycated fetal hemoglobin value, compare the glycated fetal hemoglobin value to a reference range to obtain a comparison, determine a baseline glucose control value based on the comparison, and output the baseline glucose control value and the comparison to a display for medical evaluation.
Resumen de: US20260053398A1
A blood glucose meter is provided. The blood glucose meter mainly includes a first light source, a second light source, a light sensor, a PPG circuit and a processing unit. The first light source and the second light source respectively emit a first light energy and a second light energy to human skin. The light sensor is used to convert the first light energy and the second light energy reflected off human skin or passing through human skin into a first electrical signal and a second electrical signal. The PPG circuit is configured to generate a first PPG response and a second PPG response according to the first electrical signal and the second electrical signal. A processing unit is configured to execute the following steps: performing feature extraction according to the first PPG response and the second PPG response to obtain a first set of feature values and a second set of feature values; performing an algorithm to obtain a first group of feature ratio values according to the first set of feature values and the second set of feature values; and applying the first group of feature ratio values to a regression model to obtain a blood glucose value.
Resumen de: US20260053394A1
The present subject matter discloses system (100) and method (700) for detecting and monitoring glucose levels. The system (100) comprising wearable device (200) and wearable device (200) comprising a plurality of transceivers (202) configured for transmitting plurality of power packets to one or more transceivers (202) from plurality of transceivers (202) thereby pushing each of, electrolytes under skin (500) of a user, glucose transmitters and glucose molecules towards surface of the skin (500). Plurality of electrodes (204) configured for collecting ions from body section towards the plurality of electrodes (204). Spectroscopic laser (206) and a spectroscopic detector (208) configured for detecting glucose molecules pushed towards surface of the body section. Processor (210) configured for monitoring the glucose levels according to the detection of the glucose levels.
Resumen de: US20260053395A1
An apparatus that can implement non-invasive blood glucose testing, comprising a parameter acquisition module (101), a feature determination module (102) and a blood glucose determination module (103). The parameter acquisition module (101) is used for acquiring physiological parameters of a subject the blood glucose of which is to be tested and environmental parameters of a current region in which the subject is located, the physiological parameters being acquired by using non-invasive means. The feature determination module (102) is used for obtaining, according to the physiological parameters and the environmental parameters, first input features of the subject, the first input features comprising infrared spectral features and metabolic heat integration features of the subject. The blood glucose determination module (103) is used for inputting the first input features into a blood glucose measuring model, so as to obtain a blood glucose value of the subject by means of the blood glucose measurement model. Using the described apparatus may solve the technical problems in the related technology that invasive blood glucose measuring methods cannot continuously monitor blood glucose and makes patients vulnerable to the risk of infection.
Resumen de: US20260053393A1
Glucose-sensing luminescent dyes, polymers, and sensors are provided. Additionally, systems including the sensors and methods of using these sensors and systems are provided.
Resumen de: EP4700788A2
There is provided a computer-implemented method for evaluating an insulin delivery request. The method comprises receiving patient data including glucose level data indicative of a blood glucose concentration of a patient and/or insulin data, intercepting an insulin delivery request prior to said insulin delivery request being transmitted to an insulin delivery mechanism. The insulin delivery request is configured to request delivery of an amount of insulin to the patient. The method further comprises predicting, based at least in part on the patient data, whether delivery of the amount of insulin in accordance with the insulin delivery request would result in a hypoglycemic state of the patient. If it is determined that delivery of the amount of insulin in accordance with the insulin delivery request would result in hypoglycemia, the method comprises designating the insulin delivery request as an excessive insulin delivery request. A computer-readable medium and a system are also provided.
Resumen de: EP4699534A1
An apparatus and a method for non-invasive measurement of blood glucose level are provided, which are capable of driving two or more light sources to emit lights in different wavelength bands toward a part of a body of a user (e.g., a subject), deriving amplitude values from fiducial points in at least one pulse of a respective PPG signal corresponding to each wavelength band, and estimating the blood glucose level of the user using a plurality of amplitude ratios derived from the amplitude values corresponding to different combinations of wavelength bands. The lights emitted by the two or more light sources are in different wavelength bands, indicating that the lights have different characteristics of absorption coefficients for at least glucose and hemoglobin. This helps build the regression model using more data points collected for cross-referencing and calibration compared to using one light source, thereby improving overall accuracy in the estimation of the blood glucose level of the subject.
Resumen de: EP4699535A2
The present disclosure relates to a continuous blood sugar measuring device, and provides a continuous blood sugar measuring device which is capable of minimizing additional work of a user in order to attach a body attachment unit, by manufacturing the body attachment unit to be assembled inside an applicator so that the body attachment unit can be attached to the body simply by operating the applicator and, particularly: communicating with an external terminal by providing a wireless communication chip in the body attachment unit so that simple and convenient use is possible and maintenance can easily be performed without the additional work of connecting a separate transmitter; initiating operation by a manipulation of the user, after attaching the body attachment unit to the body, so that an operation initiation time can be adjusted to a suitable time according to the need of the user; and initiating operation in a stabilized state to enable a more accurate measurement of blood sugar.
Resumen de: CA3247818A1
The invention refers to an electronic circuit configured to operate an analyte sensor, such as a glucose sensor, the circuit having at least a first and a second electrical connection configured to be connected to a first and a second electrode of the analyte sensor respectively, wherein the electronic circuit has a voltage source and a common potential conductor section electrically provided on a potential of a pole of the voltage source, wherein with the voltage source an electric potential different to the potential of the common potential conductor section can be provided to the first electrical connection; and wherein the second electrical connection is connected to the common potential conductor section through one or more common potential connection paths and wherein none of the common potential connection paths connects the second electrical connection to the common potential conductor section through fewer than three or more series-connected electronic components.
Resumen de: WO2026039036A1
An assembly for securing a glucose monitoring device and related techniques are disclosed. The assembly may include a retainer member configured to fit loosely over the glucose monitoring device without attaching or connecting to it. To that end, the retainer member and a housing of the glucose monitoring device may include respective interfacing features configured to interface with one another. The assembly further may include an adhesive overpatch configured to adhere to the retainer member and the user's skin without adhering to the glucose monitoring device. In accordance with some embodiments, removal of the adhesive overpatch from the user's skin may effectuate simultaneous removal of the retainer member from the glucose monitoring device without compromising adhesion of the glucose monitoring device to the user's skin or disrupting placement of its implanted sensor.
Resumen de: US20260048196A1
A device is disclosed for delivering medication to a user. The device comprises first and second enclosures that together form a housing of the device, the housing configured to house a reservoir for storing the medication, wherein the first enclosure includes an inner wall of the housing; and a film joined to the inner wall of the first enclosure, wherein the film and the inner wall of the first enclosure are configured to form walls of the reservoir for storing the medication.
Resumen de: AU2026200301A1
Abstract Near Infrared Spectroscopy is employed to non-invasively detect blood glucose concentrations, in a multi-sensing detection device. A multi-layered artificial neural network is used to assess these relationships of non-linear interference from human tissue, as well as differences among individuals, and accurately estimate blood glucose levels. Diffuse reflectance spectrum from tlle palm at six different wavelengths analyzed with a neural network, results in a correlation coefficient as high as 0. 9216 when compared to a standard electrochemical glucose analysis test.
Resumen de: US20260047780A1
Disclosed are miniaturized, wearable microneedle biosensor devices, systems, and methods for measuring intradermal concentrations of various metabolites (including but not limited to lactate, pyruvate, and/or glucose) in order to directly assess the viability of living tissue (e.g., human or other mammalian soft tissue). In a variety of implementations, for example, the disclosed microneedle biosensor devices are self-contained in terms of power source, sample acquisition, measurement, and data transmission capabilities, e.g., allowing it to function autonomously once placed. In some implementations, for example, the disclosed microneedle biosensor devices can assess the viability of soft tissue (e.g., skin with or without fat, fascia, or muscle) during and after reconstructive surgery in which soft tissue is repositioned, rotated, or transferred to another site in the body (including but not limited to both microvascular free tissue transfer and regional pedicled flaps).
Resumen de: WO2026038662A1
This electronic device may receive continuous blood glucose data about a user. Sensing data for identifying the state of the user may be received. The state of the user may include an activity state of the user and a biometric state of the user. The sensing data may include exercise information related to the activity state and biometric information related to the biometric state. Blood glucose patterns may be identified in time intervals in which the activity state and/or the biometric state is identified on the basis of the continuous blood glucose data and the sensing data. A personalized blood glucose pattern may be identified from the blood glucose patterns in the time intervals. The personalized blood glucose pattern may include a pattern in which blood glucose is changed according to the state. A visual object indicating that the personalized blood glucose pattern is identified by the state in a graph representing the continuous blood glucose data may be displayed through a display.
Resumen de: US20260047781A1
A porous microneedle array-based interstitial fluid glucose detection device includes a microneedle module, a colorimetric detection module, an electrochemical detection module, and a liquid transport layer. The microneedle module includes a porous microneedle array with a porosity gradient, the porosity gradually increases from the needle tip to the microneedle substrate; the porous microneedle array penetrates human epidermis and extract interstitial fluid, which is then transferred to both the colorimetric detection module and the electrochemical detection module via the liquid transport layer. Within the colorimetric detection module, glucose undergoes a reaction with the color on the colorimetric film, resulting in color development that enables rapid glucose detection; In the electrochemical detection module, glucose undergoes a redox reaction on the working electrode, resulting in the generation of a current signal for the accurate detection of glucose.
Resumen de: US20260047785A1
This document discusses, among other things, systems and methods to compensate for the effects of temperature on sensors, such as analyte sensor. An example method may include determining a temperature-compensated glucose concentration level by receiving a temperature signal indicative of a temperature parameter of an external component, receiving a glucose signal indicative of an in vivo glucose concentration level, and determining a compensated glucose concentration level based on the glucose signal, the temperature signal, and a delay parameter.
Resumen de: AU2024252061A1
Methods and devices include predicting future glucose and engagement levels for a user by receiving the user's glucose levels collected by a continuous glucose monitoring (CGM) device over a time period, receiving engagement data associated with the user, wherein the engagement data are associated with the user's medication intake, diet, physical activity, laboratory results, and education activity, determining a first glycemia risk index (GRI) value, determining, using a machine learning model and responsive to the user's glucose levels and the engagement data collected over the time period, one or more predictions for future glucose levels for the user including a prediction that a future GRI value is greater than or less than the first GRI value, and determining, using the machine learning model and responsive to the user's engagement data collected over the time period, one or more predictions for future engagement levels.
Resumen de: EP4696226A2
In some aspects, a computer-implemented method is disclosed for gathering and processing sensor data to identify a risk of impacting or causing a skin injury. The computer-implemented method can include: receiving, via a computer network, sensor feature data representing output of a user sensor configured to be worn on a limb of a user; generating activity classification model output data using the sensor feature data and an activity classification model, the activity classification model output data representing likelihoods that the sensor feature data corresponds to each of a plurality of different activity classifications; determining an activity classification from the activity classification model output data; and transmitting, via the computer network, display data representing the activity classification to a computing device configured to present the display data.
Resumen de: EP4696344A2
Embodiments of the present disclosure relate to approaches for more efficiently measuring glucose levels using a wearable drug delivery device. In some embodiments, the wearable drug delivery device may include a needle deployment component including a cannula and an optical conduit deployable into a user, the cannula operable to deliver a liquid drug to the user. The wearable drug delivery device may further include a glucose monitor including an optical sensor, the optical sensor operable to measure a light output received via the optical conduit.
Resumen de: ES1327239U
A protective device for continuous glucose monitoring sensors, characterized in that it comprises a flexible elastic band rigidly attached to a central piece (110) through two lateral openings (111) configured for its passage; and wherein said central piece (110) comprises two openings (112), upper and lower, to which a decorative fitting (130) is interchangeably connected. (Machine-translation by Google Translate, not legally binding)
Resumen de: US20260041375A1
A non-invasive biosignal measurement device based on skin effect removal, includes: a signal measurement instrument measuring a PPG signal of a measurement subject in contact with the skin on one side of a specific body part of the measurement subject; a signal reception unit receiving the PPG signal from the signal measurement instrument; and a ratio value calculation unit removing noise due to a skin effect from the PPG signal, and then calculating ratio values at different wavelengths for measuring a biosignal including blood sugar and glycated hemoglobin of the measurement subject. The signal measurement instrument includes a first sensor module including an optical barrier and a second sensor module for removing the skin effect.
Resumen de: US20260041379A1
Method for non-intrusive, needle-free detection of severe hypoglycemia onset through assessment of the cerebral arteriovenous oxygen difference. The method primarily pertains to the treatment of high-risk younger patients with Type 1 Diabetes Mellitus (T1DM) experiencing nocturnal hypoglycemia in order to prevent so called “Death in Bed” syndrome-the sudden death of young diabetic patients without any history of long-term complications.
Resumen de: US20260042778A1
0000 Novel compositions of N-desmethyl ruboxistaurin L-lactate salt and L-lactate salt polymorphs. The use of compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs to modulate GSK-3 signaling is disclosed, as is the use of compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs to inhibit protein kinase C. Methods are also disclosed of using compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs in the treatment of subjects having a neurological disease and/or psychiatric disorder, including Alzheimer's disease, bipolar disorder, depression, schizophrenia, Parkinson's disease, or neuroinflammation, as well as methods of using compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs in treating conditions associated with diabetes mellitus or its complications, or ischemia, inflammation, pulmonary hypertension, congestive heart failure, cardiovascular disease, dermatological disease, or cancer. In addition, compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs administered in combination with lithium or other treatments for bipolar disorder are also disclosed.
Resumen de: WO2026034834A1
Disclosed is a sensor module management system comprising a sensor module including a transcutaneous analyte sensor configured to perform a measurement indicating an analyte level and a sensor electronics unit communicatively connected to the transcutaneous analyte sensor, and a mobile device configured to wirelessly communicate with the sensor electronics unit. The sensor module is configured to, when it is confirmed that a command array included in a sub-advertisement event received from the mobile device includes a first command designating a group ID to which the sensor module belongs and a device ID of the sensor module, transmit a first response to the mobile device in response to the first command. The first response includes the analyte level.
Resumen de: US20260041337A1
Materials and methods of treating a patient with type 2 diabetes mellitus, metabolic syndrome, obesity, infertility, high blood pressure, hyperthyroidism, and hypothyroidism, hyperlipidaemia, osteoporosis, osteoarthritis, hypoadrenalism, polycystic ovary syndrome, or Parkinson's disease comprising administering a therapeutically effective amount of ex vivo cultured activated peripheral blood mononuclear cells (PBMCs) to the patient. The ex vivo cultured activated cells are activated and cultured in a presence of a cytokine and may be autologous or allogeneic relative to the patient.
Resumen de: EP4656127A2
The present invention relates to a continuous blood glucose measurement apparatus which, by manufacturing a body-attachable unit in an assembled state inside an applicator, minimizes the additional work by a user for attaching the body-attachable unit to the body and thus enables the body-attachable unit to be attached to the body simply by means of operating the applicator, and, by providing a wireless communication chip on the body-attachable unit and enabling communication with an external terminal, can be used in a simple and convenient manner without the additional work of connecting a separate transmitter and enables easier maintenance and management, and, by having the operation of the body-attachable unit initiated by means of the user's manipulation after being attached to the body, enables the operation initiation point to be adjusted to an appropriate point as necessary by the user, enables an operation initiation in a stabilized state and thus enables more accurate blood glucose measurement.
Resumen de: US20260041338A1
The present disclosure related to an apparatus that may be used for taking blood glucose measurements and providing individualized insulin dose recommendations wherein the apparatus is easy to use and facilitates improved diabetes control in patients. Also disclosed are related methods.
Resumen de: EP4691517A1
A processor-implemented method includes obtaining motor rotation data associated with a motor that is configured to rotate steadily to actuate a drive system for driving a plunger of a reservoir in a fluid delivery device; for each rotation of a plurality of rotations of the motor, based on a measured rotation time of the rotation of the motor and a previous maximum rotation time of the motor, determining a current maximum rotation time of the motor and storing the current maximum rotation time in a buffer; determining a coefficient of variation of motor rotation time based on data in the buffer; determining a change of the coefficient of variation of motor rotation time with respect to a baseline coefficient of variation of motor rotation time; and determining whether the plunger is detected based on a comparison of the change and a threshold value.
Resumen de: EP4693324A1
A processor-implemented method includes obtaining motor rotation data associated with a motor that is configured to rotate in strokes to drive a plunger within a reservoir in a fluid delivery device, the motor rotation data indicating time intervals between changes of position of the motor; for each stroke of a first plurality of strokes of the motor, determining an instantaneous delivery rate during one or more steps of the stroke based on the motor rotation data, and storing the instantaneous delivery rate to a buffer; determining a pre-compensation delivery rate of the fluid delivery device based on data in the buffer; and determining, in response to the pre-compensation delivery rate being lower than a pre-determined delivery rate, a first adjustment to at least one of a motor drive voltage level or a motor drive duty cycle of a drive signal of the motor.
Resumen de: AU2024252324A1
A method of therapy escalation for patients with diabetes includes receiving glucose data of a user from an in vivo glucose monitoring device, receiving first therapy information of a first therapy, wherein the first therapy includes basal insulin, calculating one or more glucose metrics based on the received glucose data, titrating a dose of the basal insulin based on the one or more glucose metrics, and determining overbasalization based on one or more of the glucose data and the first therapy information. Advantageously the system can regularly monitor glucose control of a user, detect overbasalization, provide frequent therapy intervention and adjustment, decrease a duration of intervention, and increase user adherence, outcomes, and satisfaction.
Resumen de: US20260013800A1
A computer-implemented method and system for predicting and displaying glucose values, including receiving CGM data, determining, based on the data, a plurality of first predicted glucose values (33) for a first prediction time window (30), determining, based on the data, that a hypoglycemia event is predicted to occur during a second prediction time window (31) which has a contemporaneous beginning with the first prediction time window (30) but is shorter than the first window (30), and determining a plurality of second predicted glucose values (34) for the second prediction time window (31) and displaying the plurality of second predicted glucose values (34) for the second prediction time window (31) while not displaying predicted glucose values subsequent to the second prediction time window (31).
Resumen de: US20260013801A1
Methods for predicting glucose values which involve determining a predicction time window using historical data indicative of glucose level influencing events of a person having diabetes and at least one predicted glucose level influencing event. Further disclosed are data processing systems for predicting glucose values, medical servers, user devices, and computer programs.
Nº publicación: EP4693326A2 11/02/2026
Solicitante:
INSULET CORP [US]
Insulet Corporation
Resumen de: EP4693326A2
Exemplary embodiments may provide an improved approach to automated insulin delivery by more accurately estimating the total daily insulin (TDI) of a user. As a result, less insulin is wasted by the delivery system, and the estimate of TDI more closely matches a user's actual daily insulin needs. Hence, the user need not refill the insulin reservoir excessively or need not fret unnecessarily about running out of insulin prematurely. The estimate relies on the history of actual automated insulin deliveries and thus reflects the actual insulin delivered to the user more accurately than conventional approaches.
BOPI
Sede Electrónica
